These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 23640192)

  • 1. The right drug, but from whose perspective? A framework for analysing the structure and activities of drug and therapeutics committees.
    Hoffmann M
    Eur J Clin Pharmacol; 2013 May; 69 Suppl 1(Suppl 1):79-87. PubMed ID: 23640192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Literature review on the structure and operation of Pharmacy and Therapeutics Committees.
    Durán-García E; Santos-Ramos B; Puigventos-Latorre F; Ortega A
    Int J Clin Pharm; 2011 Jun; 33(3):475-83. PubMed ID: 21416393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perspectives on Drug and Therapeutics Committee policy implementation.
    Tan EL; Day RO; Brien JA
    Res Social Adm Pharm; 2005 Dec; 1(4):526-45. PubMed ID: 17138494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure and activities of pharmacy and therapeutics committees among public hospitals in South Africa; findings and implications.
    Matlala M; Gous AG; Godman B; Meyer JC
    Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1273-1280. PubMed ID: 28776442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prioritising drug and therapeutics committee (DTC) decisions: a national survey.
    Tan EL; Day RO; Brien JA
    Pharm World Sci; 2007 Apr; 29(2):90-6. PubMed ID: 17187221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What constitutes evidence in hospital new drug decision making?
    Jenkings KN; Barber N
    Soc Sci Med; 2004 May; 58(9):1757-66. PubMed ID: 14990376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug and Therapeutics Committees in Australia: expected and actual performance.
    Weekes LM; Brooks C
    Br J Clin Pharmacol; 1996 Nov; 42(5):551-7. PubMed ID: 8951185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug and therapeutics committees in Danish hospitals: a survey of organization, activities and drug selection procedures.
    Plet HT; Hallas J; Nielsen GS; Kjeldsen LJ
    Basic Clin Pharmacol Toxicol; 2013 Apr; 112(4):264-9. PubMed ID: 23107106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A survey of drug and therapeutics committees operating in Ireland.
    Ferrando MC; Henman MC
    J Clin Hosp Pharm; 1986 Apr; 11(2):131-40. PubMed ID: 3711361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug and therapeutics committees in Nigeria: evaluation of scope and functionality.
    Fadare JO; Ogunleye O; Obiako R; Orubu S; Enwere O; Ajemigbitse AA; Meyer JC; Enato E; Massele A; Godman B; Gustafsson LL
    Expert Rev Clin Pharmacol; 2018 Dec; 11(12):1255-1262. PubMed ID: 30451035
    [No Abstract]   [Full Text] [Related]  

  • 11. "There are ways … drug companies will get into DTC decisions": How Australian drug and therapeutics committees address pharmaceutical industry influence.
    Parker L; Bennett A; Mintzes B; Grundy Q; Fabbri A; Karanges EA; Bero L
    Br J Clin Pharmacol; 2021 May; 87(5):2341-2353. PubMed ID: 33129226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies for success in creating an effective multihospital health-system pharmacy and therapeutics committee.
    Leonard MC; Thyagarajan R; Wilson AJ; Sekeres MA
    Am J Health Syst Pharm; 2018 Apr; 75(7):451-455. PubMed ID: 29572313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implementation and monitoring of decisions by pharmacy and therapeutics committees in South African public sector hospitals.
    Mashaba TP; Matlala M; Godman B; Meyer JC
    Expert Rev Clin Pharmacol; 2019 Feb; 12(2):159-168. PubMed ID: 30407089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving pharmacy and therapeutics committee operations.
    Cohen MR; Klapp D; Miller KB; Shaffer VL; Slotfeldt M; Miller DE
    Am J Hosp Pharm; 1984 Sep; 41(9):1767-77. PubMed ID: 6496511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving the presentation of drug information to pharmacy and therapeutics committees for formulary decisions.
    Sterné SC; Uchida KM; Iteen SA
    Am J Health Syst Pharm; 1996 May; 53(10):1162-4. PubMed ID: 8734677
    [No Abstract]   [Full Text] [Related]  

  • 16. Establishing and strengthening a medicine and therapeutics committee in a medical college in Nepal: initial experiences.
    Shankar PR; Humagain B; Piryani RM; Jha N; Osti B
    Pharm World Sci; 2009 Apr; 31(2):241-5. PubMed ID: 19058026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug and therapeutics committees: the relationships among structure, function, and effectiveness.
    Plumridge RJ; Stoelwinder JU; Rucker TD
    Hosp Pharm; 1993 Jun; 28(6):492-3, 496-8, 508. PubMed ID: 10126453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Managing conflicts of interest in pharmacy and therapeutics committees: A proposal for multicentre formulary development.
    Friesen P; Caplan AL; Miller JE
    J Clin Pharm Ther; 2020 Apr; 45(2):249-255. PubMed ID: 31657022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The application of adverse drug reaction data to drug choice decisions made by pharmacy and therapeutics committees. An Australian perspective.
    Weekes LM; Day RO
    Drug Saf; 1998 Mar; 18(3):153-9. PubMed ID: 9530535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using health outcomes data to inform decision-making: formulary committee perspective.
    Janknegt R
    Pharmacoeconomics; 2001; 19 Suppl 2():49-52. PubMed ID: 11700789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.